AVROBIO is a leading clinical-stage gene therapy company based in Cambridge, MA. They are dedicated to developing highly personalized gene therapies for individuals with genetic diseases, aiming to halt or reverse disease progression with a single dose of therapy. Their investigational gene therapies start with the patient's own stem cells and are being developed for serious lysosomal disorders. AVROBIO's approach involves utilizing their state-of-the-art platform, called plato, to optimize gene therapies and solve the challenges associated with gene therapy.
With a goal to enable individuals with genetic diseases to live longer and free from disease progression, AVROBIO strives to deliver freedom for life. They are committed to innovation, collaboration, and dedication in bringing pioneering therapies to individuals living with genetic diseases. Through their pipeline of therapies and partnerships with patient advocacy groups, AVROBIO is working towards providing effective treatments and support for patients and their families.
Generated from the website